Market Overview

UPDATE: Goldman Sachs Downgrades DaVita to Neutral on Near-Term Momentum Slowdown

Share:
Related DVA
Stephen Mandel's Lone Pine Capital Loves Tech, Consumer Stocks
Worst Performing Industries For February 13, 2015
InsiderInsights.com Daily Round Up 3/30/15: VEEV, VNCE, PRSS, OGS (Seeking Alpha)

Goldman Sachs downgraded DaVita (NYSE: DVA) from Buy to Neutral and maintained a $120.00 price target.

Goldman Sachs noted, "We downgrade DVA to Neutral from Buy as we think the stock is now fairly valued and as we see more upside in other areas of our coverage. While our outlook for core dialysis remains solid and we continue to see strong long-term growth potential in physician (HCP) and dialysis integrated care, we expect slower growth with less upward momentum to our/Street view over the next 12-24 months."

DaVita closed at $119.21 on Thursday.

Latest Ratings for DVA

DateFirmActionFromTo
Mar 2015Deutsche BankMaintainsHold
Nov 2014JP MorganMaintainsOverweight
Sep 2014KeyBancDowngradesBuyHold

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (DVA)

Around the Web, We're Loving...